Biomedicine Xagena
Findings from two pre-planned, subgroup analyses of the landmark ZUMA-7 trial of Axicabtagene ciloleucel ( Yescarta ), which led to the U.S. Food and Drug Administration’s ( FDA ) expanded approval o ...
The US Food and Drug Administration ( FDA ) has granted accelerated approval for Kymriah ( Tisagenlecleucel ) for the treatment of adult patients with relapsed or refractory ( r/r ) follicular lympho ...
Thr U.S. Food and Drug Administration ( FDA ) has approved Breyanzi ( Lisocabtagene maraleucel ), a CD19-directed chimeric antigen receptor ( CAR ) T cell therapy, for the treatment of adult patients ...
Longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus ( Brexucabtagene autoleucel; Brexu-cel ). The three-year follow-up of ZUMA-2, a phase 2 global, multi-cent ...
The U.S. Food and Drug Administration ( FDA ) has approved Yescarta ( Axicabtagene ciloleucel ), a CAR T-cell therapy, for adult patients with large B-cell lymphoma that is refractory to first-line ch ...
The European Commission ( EC ) has granted conditional marketing authorisation of Carvykti ( Ciltacabtagene autoleucel; Cilta-cel ) for the treatment of adults with relapsed and refractory multiple my ...
The European Commission ( EC ) has granted marketing authorization for Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric antigen receptor ( CAR ) T cell immunotherapy, for the ...
The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel ), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory ( r/r ) follicular lymphoma ( FL ) after ...
Positive topline results from the RAISE trial evaluating investigational treatment Zilucoplan, a self-administered, subcutaneous ( SC ) peptide inhibitor of complement component 5 ( C5 inhibitor ), ve ...
The European Commission ( EC ) has granted marketing authorization for Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric antigen receptor ( CAR ) T cell immunotherapy, for the ...
Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, have shown reversible hepatic effects in animals that received the BNT162b2 injection. A recent study has s ...
Cancer patients rarely die from the primary tumor but rather from the metastases, even after successful tumor surgery. This is because cancer cells sometimes spread to other parts of body early in the ...
EMA ( European Medicne Agency ) has recommended granting a marketing authorisation in the European Union for the gene therapy Skysona ( Elivaldogene autotemcel ) for the treatment of children with cer ...
Aromatic L-amino acid decarboxylase ( AADC ) deficiency is a rare genetic disorder characterized by deficient synthesis of dopamine and serotonin. It presents in early infancy, and causes severe devel ...
Regkirona is a medicine used for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of their disease becoming severe. Regkirona contains the active subst ...
